Using Blood Markers to Diagnose Stroke and Tell Its Type

This patent describes a two-step method for diagnosing a stroke and then determining if it's an ischemic stroke or a transient ischemic attack (TIA) by measuring specific protein levels in a patient's blood.

What it covers

The patent outlines a method for diagnosing a stroke by first measuring the concentration of at least two specific biomarkers in a blood sample. These biomarkers must include at least one from a group like ICAM-1, L-selectin, P-selectin, or VCAM-1, combined with another from a broader list including IL-6, sTNFR1, D-dimer, and CRP. The measured levels are then compared to normal control values. If a stroke is diagnosed, a second method is used to tell if it's an ischemic stroke or a 'mini-stroke' (TIA). This second step involves measuring VCAM-1 and at least one other biomarker from h-FABP, IL-6, or CRP, and comparing those levels to control values from TIA patients. For example, a doctor could take a blood sample, test for elevated ICAM-1 and D-dimer to initially diagnose a stroke, and then, if positive, test for VCAM-1 and h-FABP to differentiate it from a TIA.

What it doesn't cover

• —Does not cover diagnosing stroke using only a single biomarker; at least two are required by claim 1.
• —Does not cover methods that do not include at least one biomarker from the specific group of ICAM-1, L-selectin, P-selectin, or VCAM-1 in the initial diagnosis.
• —Does not cover methods that differentiate stroke types without measuring VCAM-1 in the second step.
• —Does not cover diagnosing stroke using imaging techniques like MRI or CT scans, as it focuses on *in vitro* (blood sample) biomarker analysis.
• —Does not cover diagnosing other neurological conditions that might present with similar symptoms but are not strokes or TIAs.

The clever bit

The novelty lies in the specific two-step diagnostic process: first, using a defined combination of biomarkers to identify a stroke, and then, if a stroke is detected, using a different, specific set of biomarkers to differentiate between an ischemic stroke and a transient ischemic attack (TIA) by comparing to TIA-specific control values.

Why it matters

Accurately and quickly diagnosing a stroke is critical because timely treatment can significantly reduce brain damage and improve patient outcomes. This patent offers a blood-based approach, which could potentially provide faster results than some imaging methods, especially in emergency settings. Distinguishing between an ischemic stroke and a TIA is also important for guiding subsequent treatment and prevention strategies.

Real-world examples

• 1.Emergency room diagnostic panels for suspected stroke patients
• 2.Point-of-care testing devices for rapid stroke assessment
• 3.Clinical laboratory tests for stroke differential diagnosis